• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Introduction to 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride (CAS No. 84050-21-5)

The compound 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride, identified by its CAS number 84050-21-5, represents a significant advancement in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the quinazoline class of heterocyclic structures, which have garnered considerable attention due to their diverse biological activities and potential therapeutic applications. The presence of functional groups such as amino, methoxy, and aldehyde moieties in its molecular framework endows it with unique chemical properties that make it a promising candidate for further investigation in drug discovery and development.

Quinazoline derivatives are well-documented for their role in various pharmacological contexts, including anticancer, antimicrobial, and anti-inflammatory properties. Among these derivatives, compounds featuring a piperazine moiety exhibit enhanced binding affinity to biological targets, which is crucial for the development of small-molecule drugs. The specific arrangement of functional groups in 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride suggests potential interactions with enzymes and receptors involved in critical cellular pathways.

Recent studies have highlighted the importance of quinazoline-based compounds in addressing unmet medical needs. For instance, modifications in the quinazoline core have led to the discovery of novel agents that inhibit kinases and other enzymes implicated in cancer progression. The aldehyde group in 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride provides a reactive site for further chemical derivatization, enabling the synthesis of more complex molecules with tailored biological activities. This flexibility is particularly valuable in medicinal chemistry, where structural optimization is essential for improving drug efficacy and selectivity.

The hydrochloride salt form of this compound enhances its solubility and stability, making it more suitable for pharmaceutical formulations. Solubility is a critical parameter for drug delivery systems, as it influences bioavailability and therapeutic outcomes. The improved solubility of 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride may facilitate its use in oral or injectable medications, broadening its potential applications.

In the realm of oncology, quinazoline derivatives have shown promise as inhibitors of tyrosine kinases, which are overactive in many cancers. The amino and methoxy substituents in 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride may contribute to its ability to modulate kinase activity by interacting with key residues in the enzyme's active site. Additionally, the piperazine ring can form hydrogen bonds with polar regions of biological targets, enhancing binding affinity.

Advances in computational chemistry have enabled the rational design of quinazoline-based drugs by predicting molecular interactions at an atomic level. Virtual screening techniques can identify lead compounds like 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride that exhibit high binding affinity to specific proteins or enzymes. This approach has accelerated the drug discovery process and reduced the time required to bring new therapies to market.

The synthesis of 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride involves multi-step organic reactions that require precise control over reaction conditions. Key synthetic steps include condensation reactions to form the quinazoline core, followed by functional group modifications to introduce the amino and methoxy groups. The final step involves conversion of the aldehyde group into its hydrochloride salt form to improve stability and solubility.

Evaluation of 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride in preclinical studies has revealed intriguing biological profiles. In vitro assays have demonstrated its ability to inhibit certain kinases with IC50 values comparable to those of known therapeutic agents. These findings suggest that further investigation may uncover new therapeutic applications for this compound or derivatives thereof.

The development of novel drug candidates is often accompanied by challenges related to toxicity and pharmacokinetics. However, preliminary toxicity studies on 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride indicate that it exhibits low toxicity at relevant concentrations. This favorable safety profile enhances its potential as a lead compound for further development.

Future research on 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride may focus on optimizing its pharmacological properties through structural modifications. By fine-tuning the positions and types of substituents on the quinazoline core, researchers can enhance binding affinity, reduce side effects, and improve overall therapeutic efficacy.

The integration of high-throughput screening (HTS) technologies has revolutionized drug discovery by enabling rapid evaluation of large libraries of compounds for biological activity. HTS can be employed to assess the potency and selectivity of 4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde Hydrochloride against various targets, facilitating identification of optimal derivatives for clinical development.

In conclusion, 4-(4-Amino - 6 , 7 - dimethoxy - 2 - quin az olin yl ) - 1 - piper az ine car box al de hy droch lor ide ( CAS No . 84050 - 21 - 5 ) represents a promising candidate for further exploration in pharmaceutical research . Its unique structural features , combined with favorable solubility and preliminary biological activity , make it an attractive lead compound for developing new therapies . Continued investigation into this compound and its derivatives holds significant potential for advancing treatments across multiple therapeutic areas .

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)